The Morning in One Line

The session opened with a clear macro overhang and never shook it. Rate-hike anxiety — not earnings disappointments — is the dominant force pulling equities lower, and the afternoon will test whether any catalyst can shift that narrative.

The Fed Concern Is Running the Show

The central story Thursday is investor repricing of the Federal Reserve's policy trajectory. Specifically, markets are grappling with the possibility that the Fed could raise its benchmark federal funds rate before the end of 2026 — a scenario that, until recently, few had treated as a serious base case.

The mechanics are straightforward. When rate-hike expectations rise, borrowing costs across the economy follow, corporate profit margins compress, and equities become relatively less attractive compared to bonds. What makes today's move notable is that it came against a backdrop of broadly constructive corporate news — suggesting the macro concern is carrying enough weight to override positive signals elsewhere.

No single Fed statement or economic data release appears to have been the immediate trigger. The anxiety reflects accumulated uncertainty about the inflation outlook rather than a specific catalyst. That ambiguity makes it harder to trade around: there is no single piece of data to wait for, no scheduled Fed speaker to reframe the picture.

Goldman Sachs added a second layer of macro concern by warning that renewed hostilities in the Persian Gulf could disrupt global oil supplies. The bank had previously forecast an oil glut — more supply than demand requires — making the reversal in tone significant. Elevated crude prices feed back into inflation expectations, which in turn reinforce the case for tighter monetary policy. That feedback loop is now an active part of the market's calculus.

AstraZeneca's $27 Billion Single-Session Loss

The sharpest single-stock event of the session belongs to AstraZeneca (AZN) and partner Ionis Pharmaceuticals (IONS). Their drug Wainua, which targeted ATTR-CM — a progressive cardiac condition caused by abnormal protein buildup around the heart — failed to outperform a placebo in a pivotal clinical trial.

Pivotal trials are the final large-scale controlled studies required before regulators will consider approving a drug. A failure at this stage typically ends a drug's commercial prospects entirely, eliminating years of development investment and projected future revenue in a single data readout. AstraZeneca lost approximately $27 billion in market capitalization on the news. Ionis, which co-developed the drug, also faced significant fallout.

For AstraZeneca, the result removes what had been an anticipated addition to its cardiovascular pipeline. The loss underscores a persistent truth about pharmaceutical investing: even well-resourced companies with diversified portfolios remain exposed to binary trial outcomes that no amount of scale can fully hedge.

AI Capital Is Still Moving — Just Through Different Channels

While the macro tape is negative, AI-linked deal flow is telling a different story about where long-term capital is being committed.

Apple (AAPL) extended its chip supply agreement with Broadcom (AVGO) through 2031 in a deal expected to exceed $30 billion — a long-duration commitment that reinforces Broadcom's position as a critical supplier of custom silicon for Apple's AI workloads. Separately, Apollo Global Management is bringing a $35 billion private credit financing package to market for Broadcom and AI startup Anthropic, aimed at expanding AI infrastructure capacity. Private credit — debt arranged outside traditional bank channels — has grown rapidly as an asset class, and a transaction of this scale signals that institutional investors are willing to commit at terms unavailable in public bond markets.

AMD announced plans to deploy six gigawatts of GPU capacity for Meta under a new partnership. That figure is a measure of compute scale that signals the depth of hyperscaler demand for non-Nvidia processors. Taken together, these three transactions illustrate how AI capital spending is flowing through multiple layers of the supply chain simultaneously — chip design, manufacturing commitments, and private debt markets — even on a day when the broader equity tape is under pressure.

SpaceX and the Passive Buying Mechanic

SpaceX (SPCX) has been added to the Nasdaq-100, the index of the 100 largest non-financial companies on the Nasdaq exchange. The inclusion is expected to trigger approximately $4.3 billion in forced purchases by passive index-tracking funds — vehicles that must hold every index constituent in proportion to its weight, regardless of their own view on valuation.

For investors in Nasdaq-100 products including the widely held QQQ ETF, the addition changes the composition of what they own, adding aerospace and satellite exposure. The mechanics of this trade are worth watching as index rebalancing flows settle over the coming sessions.

A Contrasting Signal From Biotech M&A

Not all healthcare news is negative. Vertex Pharmaceuticals (VRTX) agreed to acquire Crinetics Pharmaceuticals (CRNX) for approximately $10 billion, sending Crinetics shares up roughly 99% over the course of the week. The deal extends Vertex's reach beyond its established cystic fibrosis franchise into endocrine and metabolic diseases, and adds to a broader pattern of large pharmaceutical companies using acquisitions to replenish pipelines rather than relying solely on internal research. The contrast with AstraZeneca's trial failure is instructive: the same sector that produced Thursday's biggest single-stock loss also produced one of the year's more dramatic M&A-driven gains.

The Afternoon Setup

The session's direction hinges on whether any incremental clarity emerges on the Fed's rate path. Without a scheduled Fed speaker or major economic release to shift the narrative, the default trajectory is continued pressure on rate-sensitive equities.

Watch AZN and IONS for any management response to the Wainua failure — guidance on pipeline strategy or restructuring could stabilize or extend the damage. Monitor crude prices for any follow-through on Goldman's Persian Gulf warning; a meaningful move higher in oil would reinforce the inflation-and-rates feedback loop that is already weighing on sentiment. And track the SpaceX passive-buying flows in SPCX as index rebalancing demand works through the market structure over the next few sessions.